HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Humacyte, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.40−0.03 (-6.50%)
Close on Oct 19, 2026
- Market cap
- $93.93M
- P/E (TTM)
- –
- Dividend yield
- –
Humacyte, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| Product [Member] | $1.39M | $0 | 68.2% | – |
| Contract Revenue [Member] | $649.00K | $0 | 31.8% | – |
By region
From the segment and revenue-disaggregation notes of Humacyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.